Daclatasvir-sofosbuvir combination therapy for chronic hepatitis C virus infection: progress in clinical studies / 中华肝脏病杂志
Chinese Journal of Hepatology
; (12): 147-150, 2018.
Article
de Zh
| WPRIM
| ID: wpr-806107
Bibliothèque responsable:
WPRO
ABSTRACT
All-oral, pan-genotypic combination of direct-acting antiviral agents is currently clinically prescribed trends in the management of chronic hepatitis C virus infection. The combination of daclatasvir and sofosbuvir has proven strong antiviral activity across all common genotypes in clinical trials and real world studies. Furthermore, it can be safely used in patients with advanced liver disease, HCV/HIV co-infection, or HCV recurrence after liver transplantation, more patients will gain clinical benefits. We aim to summarize the clinical progress about this combination.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Journal of Hepatology
Année:
2018
Type:
Article